
==== Front
Res Pract Thromb Haemost
Res Pract Thromb Haemost
Research and Practice in Thrombosis and Haemostasis
2475-0379
Elsevier

S2475-0379(24)00234-6
10.1016/j.rpth.2024.102539
102539
Review
How to undertake procedures while on antiplatelet agents: a hematologist's view
Swan Dawn @DSwanhaem
1
Turner Robert 2
Douketis James 3
Thachil Jecko jecko.thachil@mft.nhs.uk
4∗
1 Department of Haematology, Austin Health, Melbourne, Victoria, Australia
2 Department of Intensive Care, St Vincent’s Hospital, Melbourne, Victoria, Australia
3 Department of Medicine, St. Joseph’s Healthcare Hamilton and McMaster University, Hamilton, Ontario, Canada
4 Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
∗ Correspondence Jecko Thachil. jecko.thachil@mft.nhs.uk
05 8 2024
8 2024
05 8 2024
8 6 1025391 4 2024
28 5 2024
27 6 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Cardiovascular diseases (CVDs) are the leading cause of mortality globally while also contributing to excess health system costs. Significant advancements have been made in the understanding and prevention of deaths from CVD. In addition to risk factor modifications, one of the key developments in this area is the appropriate prescribing of antiplatelet medications for secondary prevention of CVD. With the advent of vascular devices, there has been an increased use of potent antiplatelet agents to mitigate thrombosis risk. A well-recognized, albeit rare complication of antiplatelet drugs is the heightened risk of bleeding. This adverse effect is particularly relevant when a patient receiving these medications may require an urgent surgery. In addition, for elective surgeries, although these drugs can be withheld, there may be some situations when interruption of antiplatelet agents, even for short duration, may lead to thrombotic events. There are no robust guidelines on how to manage these clinical scenarios, although there have been some important studies published recently in this area. In this review, we provide our approach to patients on antiplatelet drugs who may require urgent surgeries or surgical interventions.

Graphical abstract

Essentials

• Several guidelines provide recommendations concerning interruption of antiplatelet therapy for elective procedures or interventions.

• This articles aims to provide an update on these recommendations as well as including pragmatic approaches for urgent cases.

• Bridging therapy therapy may be required for select situations where there is high thrombotic risk. The evidence base underpinning this is not rigorous, and requires case-by-case multidisciplinary discussion.

• Aiming to minimise interruption of antiplatelet therapy is recommended for the majority of lower thrombotic risk cases.

Keywords

anesthesia
antiplatelet
aspirin
bleeding
clopidogrel
prasugrel
surgery
ticagrelor
==== Body
pmc1 Introduction

The global burden of diseases, injuries, and risk factors study, which has tracked trends in death and disability since 1990, reports that cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide [1]. The global prevalence of CVD nearly doubled from 271 million people in 1990 to 523 million in 2019, with a proportionally smaller increase in mortality, from 12.1 to 18.6 million [2]. Since the advent of routine percutaneous coronary intervention (PCI) and a worldwide increased focus on cardiovascular risk factor modification (hypertension, hyperlipidemia, diabetes mellitus, smoking cessation, etc.), deaths from CVD have actually decreased by over 50% in some countries [[3], [4], [5], [6]]. Alongside these measures, antiplatelet therapy forms a therapeutic cornerstone for the management of CVD, and, as such, prescriptions for P2Y12 inhibitors have increased significantly in recent years [7]. The issue of management of patients who are receiving antiplatelet therapy and require a surgery or procedure is common. In a higher-risk group of patients with recent PCI or coronary stenting, 4% to 8% of patients will require major surgery in the year that follows [8].

Against this background, the aim of this review was to assess the available evidence and published guidelines that inform the management of patients who are taking antiplatelet therapy and require an elective or urgent surgery. Specifically, we also consider evidence relating to the role of antiplatelet bridging agents, platelet transfusions, and antiplatelet reversal agents in this clinical setting [9].

2 The Antiplatelet Agents and their Mechanism of Action

The most frequently prescribed antiplatelet drugs are aspirin and the P2Y12 inhibitors clopidogrel, ticagrelor, and, to a lesser extent, prasugrel, which is usually only chosen in certain high-risk patient groups [10]. The pharmacologic properties of these and other antiplatelet agents are shown in Table 1 [[11], [12], [13]]. Antiplatelet monotherapy usually comprises aspirin or clopidogrel, whereas dual antiplatelet therapy (DAPT) refers to the combination of aspirin with a P2Y12 inhibitor. Briefly, aspirin derives antiplatelet activity by irreversible acetylation of serine-530 of the COX-1 enzyme, leading to near-complete inhibition of thromboxane A2 production, preventing prostanoid-mediated platelet aggregation [14]. The P2Y12 inhibitors prevent adenosine 5' diphosphate (ADP) from binding to the P2Y12 receptor, impeding subsequent exposure of glycoprotein (GP) IIb/IIIa and thereby preventing fibrinogen-mediated platelet activation [15].Table 1 Pharmacokinetic properties of the antiplatelet agents available and in clinical trials.

Drug	Mechanism of action	Route of administration	Reversible or irreversible	Half-life	Time to recover platelet function after drug withdrawal	
Aspirin	COX-1 inhibitor	Oral	Irreversible	15-20 min	30% at 48 h	
Clopidogrel	P2Y12 inhibitor	Oral	Irreversible	6-8 h	40% at 3 d	
Prasugrel			Irreversible	7 h	2-3 d	
Ticagrelor			Reversible	7-9 h	57% at 24 h	
Ticlopidine			Irreversible	8-12 h	3-14 d	
Abciximab	GPIIb/IIIa inhibitor	i.v.	Reversible	10-15 min	12 h	
Eptifibatide				2.5 h	2-4 h	
Tirofiban				2 h	2-4 h	
Cangrelor				3-6 min	3-6 min	
Vorapaxar	Protease-activated receptor-1 inhibitors	Oral	Reversible	5-13 d	4-8 wk	
Cilostazol	Phosphodiesterase inhibitors-3 or -5 inhibitors	Oral	Reversible	11 h	12-16 h	
Dipyridamole		Sildenafil and dipyridamole can be i.v.		10-12 h	-	
Sildenafil				4-6 h	-	
Tadalafil				17.5 h	24-36 h	
Vardenafil				5 h	-	
Iloprost	PGI2 analog	i.v.	Reversible	20-30 min	2 h	
Epoprostenol			Reversible	<1 min	<10 min	
BMS-986120 and BMS-986141	Protease-activated receptor-4 antagonist	In trials	Reversible	45-84 h
34-45 h	∼24 h
>24 h	
Anfibatide	GPIb-V-IX complex inhibitor		Reversible	5-7 h	8 h	
Revacept(advanceCOR)	GPVI competitive inhibitor		Reversible	87-137 h	48 h	
Glenzocimab	GPVI inhibitor-Ab		Reversible	9.6 h	25%-55% 24 h	
VLX-1005	12-Lipoxygenase inhibitor		Irreversible	2.9 h	-	
Ab, antibody; GP, glycoprotein; i.v., intravenous.

3 Elective Surgery and Low-Risk Interventional Radiology Procedures

The perioperative management of patients taking antiplatelet agents involves multiple considerations, including the indication for antiplatelet use (eg, primary vs secondary prevention), use of DAPT or monotherapy, the urgency of surgery, and associated bleeding and thrombotic risks [16,17]. Risk prediction tools such as the Revised Cardiac Risk Index and the National Surgical Quality Improvement Program perform poorly at predicting major adverse cardiac events (MACEs) and are not validated for predicting MACEs in the context of perioperative withholding of antiplatelet agents. Similarly, the CHA2DS2-VASc score has poor predictive utility for perioperative stroke [[18], [19], [20], [21], [22]]. The American Heart Association and European Society of Cardiology (ESC)/European Society of Anaesthesiology and Intensive Care guidelines for perioperative evaluation of cardiac risk recommend utilizing a Bayesian inference approach that incorporates patient and surgical factors [23,24]. Similarly, predicting surgical-associated bleeding risk on a broad level is challenging as scores such as HAS-BLED and the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool have poor utility in this clinical setting [21]. Limited evidence suggests that specific surgery types (eg, cancer surgery) and selected comorbidities (eg, prior bleeding) may affect perioperative bleeding risk [25,26]. Empiric classifications of surgery and procedure types according to bleeding risk are available to estimate individual bleeding [27]. Patient-related factors that may affect bleeding risk include concomitant renal or liver disease, use of nonsteroidal anti-inflammatory drugs, and other medications that impair hemostasis [9].

3.1 Aspirin

There is uncertainty as to the optimal perioperative management of patients taking antiplatelet monotherapy with aspirin (ASA) in patients having a low-to-moderate bleeding risk surgery, whereas interruption is suggested for interventions associated with very high bleeding risk, such as intracranial and spinal surgeries or neuraxial/deep nerve root procedures [21,[28], [29], [30], [31], [32], [33]]. The POISE-2 trial, which involved 10,010 patients having elective noncardiac surgery (most commonly orthopedic, general, or urological/gynecologic procedures), randomized allocated patients to continue or stop ASA (continuation stratum) or to initiate or not take ASA (initiation stratum) perioperatively [34]. Although the group that took ASA perioperatively experienced a significantly higher incidence of major bleeding (4.6% vs 3.8%; hazard ratio, 1.2; 95% CI, 1.01-1.50), there was no significant difference in bleeding among patients in the continuation stream (4.6% vs 4.1%; hazard ratio, 1.1; 95% CI, 0.84-1.48), who either continued or stopped ASA, and this subgroup may be most representative of patients assessed in practice who are already taking ASA. In a subgroup of 470 patients who had undergone PCI and stenting, perioperative ASA continuation was associated with significantly lower rate of nonfatal myocardial infarction (MI) at 30 days (absolute risk reduction, 5.9%; 95% CI, 1.0%-10.8%) without a significant increase in major and life-threatening bleeding [35]. If a clinical decision is made to withhold aspirin prior to high-risk bleeding procedures, adequate recovery of platelet function for hemostasis can be expected within 3 to 5 days following cessation [[36], [37], [38]]. The ESC and 2022 American College of Chest Physician (CHEST) guidelines suggest consideration of ASA continuation according to individual bleeding and thrombosis risk; if ASA interruption occurs, it is recommended to stop ≤7 days prior to high bleeding risk surgery, whereas the British Society for Haematology guidelines and the French Working Group on Perioperative Haemostasis in collaboration with the French Society of Anaesthesia and Intensive Care Medicine suggest 3 days of ASA interruption is sufficient [[28], [29], [30],39]. For patients taking high-dose ASA, the American Society of Regional Anesthesia and Pain Medicine, European Society of Regional Anaesthesia and Pain Therapy, and Society of Interventional Radiology recommend discontinuing aspirin ≥3 days prior to a planned intervention [31,33].

3.2 P2Y12 inhibitors

DAPT is commonly used in patients who have undergone PCI with coronary stent insertion. Up to 14% of these patients may require surgery in the year following PCI [40]. Rates of MACEs (death, MI, and stent thrombosis) are particularly high during the first 6 weeks after stenting, at 10% to 45%, but fall to 4% at 6 months and return to preprocedural levels after 12 months [41]. Such risks are dependent upon preexisting comorbidities and surgical factors [20], as well as stent-related factors [42,43].

Timing of discontinuation depends upon drug pharmacokinetics and patient and procedural bleeding risk. In the CURE study of ASA and clopidogrel compared with ASA monotherapy in unstable angina, 2072 individuals underwent coronary artery bypass grafting (CABG). If clopidogrel was discontinued ≥5 days preoperatively along with ASA continuation, this was not associated with an increased risk of bleeding observed compared with continuing ASA alone [44]. In 1261 patients with acute coronary syndrome (ACS) requiring cardiac surgery, DAPT with aspirin and ticagrelor was associated with similar rates of bleeding in the PLATO study compared with aspirin/clopidogrel. In this study, ticagrelor was held 1 to 3 days before surgery and clopidogrel was held 5 days before surgery. Aspirin was continued throughout [45]. In comparison, the addition of prasugrel was associated with significantly more bleeding, as determined by 12-hour chest tube loss in 346 patients undergoing CABG within the TRITON-TIMI trial [46]. In addition, platelet inhibition persists for longer following prasugrel cessation [47].

The majority of the current major guidelines recommend that ticagrelor and clopidogrel should be ceased 5 days before surgery, and prasugrel requires 7 days, albeit with very low quality of evidence [28,29,39]. The 2022 CHEST guideline suggests 3 to 5 days for ticagrelor, whereas the current iteration of the ESC guideline has reverted to 5 days, having previously suggested that 3 days is sufficient [30,43].

For patients who require noncardiac surgery with a history of recent MI or who have undergone PCI and stenting, surgery should ideally be postponed until DAPT is no longer required [29]. Both the ESC and American Heart Association currently recommend 6 months of DAPT after PCI and 1 year following ACS [48]. While the need for DAPT immediately post-PCI was reaffirmed by the recent STOPDAPT-3 study, which demonstrated prasugrel monotherapy to be associated with increased rates of in-stent thrombosis compared with DAPT [49], a number of other trials have demonstrated that 1 to 3 months of DAPT is likely sufficient. A meta-analysis of 4 such studies (MASTER-DAPT, TWILIGHT, TICO, and STOPDAPT-2 [[50], [51], [52], [53]]) reported no increase in MACEs or in-stent thrombosis, with reduced levels of major and clinically relevant nonmajor bleeding compared with standard duration DAPT [54].

Current recommendations suggest that a minimum period of 1 month should have elapsed after elective PCI and 3 months after ACS before a patient has nonemergency noncardiac surgery [29]. Should future guidelines shorten the required period of dual antiplatelets, temporary discontinuation of P2Y12 inhibition may be required for significantly fewer patients. If surgery is required within 1 month of PCI and stenting, bridging may be a consideration, as discussed later. A summary of the guideline recommendations for elective procedures is shown in Table 2.Table 2 Guideline recommendations in elective surgery.

Guideline	Elective procedures	Neuraxial procedures	Bridging	
ESC/European Society of Anaesthesiology and Intensive Care 2022	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 3-5 d prior
Prasugrel: 7 d prior	No specific recommendations	Consider in high-risk cases with cangrelor, tirofiban, or eptifibatide	
ESC/European Association for Cardio-Thoracic Surgery 2017	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 3 d prior
Prasugrel: 7 d prior	No specific recommendations	Consider if surgery is <1 mo after stent insertion	
ESC/European Society of Anaesthesiology 2014	Continue aspirin	No specific recommendations	Consider for very high thrombotic risk patients	
Clopidogrel: discontinue 5 d prior	
Ticagrelor: 3-5 d prior	
Prasugrel: 7 d prior	
British Society for Haematology 2016	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 5 d prior
Prasugrel: 7 d prior	Continue aspirin
Discontinue P2Y12 inhibitors 7 d prior	No specific recommendations	
American College of Chest Physicians 2022	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 3-5 d prior
Prasugrel: 7 d prior	No specific recommendations	Not routinely recommended; consider in select high-risk procedures	
Japanese Circulation Society 2020	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 3 d prior
Prasugrel: 7 d prior	No specific recommendations	Not recommended	
Clinical Excellence Commission, Australia 2018	Continue aspirin
Clopidogrel: discontinue 7 d prior
Ticagrelor: 5 d prior
Prasugrel: 7 d prior
Ticlopidine: 14 d prior	Continue aspirin
Clopidogrel: discontinue 5 d prior
Ticagrelor: 5 d prior
Prasugrel: 7 d prior
Ticlopidine: 14 d prior	Not recommended	
ESC, European Society of Cardiology.

4 Neuraxial Anesthesia/Deep Plexus Regional Anesthesia/High-Risk interventional Radiology/Pain Procedures

The main concern as to the safety of using antiplatelet agents around neuraxial procedures relates to the risk for spinal hematoma, a rare but potentially devastating complication [55]. However, relevant data are limited. There was no increase in expected bleeding following spinal or epidural anesthesia in 193 patients receiving low-dose ASA prior to orthopedic surgery [56], nor was bleeding increased after epidural anesthesia with ASA use for preeclampsia in 1422 women compared with 1361 who were allocated placebo. In this study, patients continued antiplatelet therapy until the day of delivery [57]. There is less available evidence regarding the P2Y12 inhibitors. Guidelines either do not address this question or recommend a similar discontinuation as that for elective surgery [28,29,33,39,58]. The evidence for deep plexus blockade, high-risk interventional radiology, and pain procedures is also scarce, and guidelines recommend following guidance for neuraxial blockade due to lack of evidence in this field [21,[31], [32], [33]]. A general approach to patients on DAPT who require elective procedures or neuraxial anesthesia is shown in Table 3 and Figure 1. A summary of the guideline recommendations is shown in Table 4.Table 3 Author’s recommendations for elective surgery and neuraxial anesthesia.

Drug	Elective surgery	Neuraxial anesthesia	
Aspirin	Continue unless very high risk of bleeding, then stop 5 d before	No contraindication following a risk-benefit analysis	
Clopidogrel	5-7 d	5-7 d	
Prasugrel	7 d	7 d	
Ticagrelor	5 d	5 d	

Figure 1 An algorithm for the management of antiplatelet agents around surgery or interventions.

Table 4 Guideline recommendations in neuraxial anesthesia/deep plexus regional anesthesia/high-risk interventional radiology and pain procedures.

Guideline	Neuraxial anesthesia/deep plexus regional anesthesia/high-risk interventional radiology/pain procedures	
The Canadian Association for Interventional Radiology and The Cardiovascular and Interventional Radiological Society of Europe 2019	Continue aspirin	
Discontinue P2Y12 inhibitors 5 d prior	
ESAIC/ESRA 2022	Continue low-dose aspirin
High-dose aspirin: discontinue 3-7 d prior
Clopidogrel: 7 d prior
Ticagrelor: 5-7 d prior
Prasugrel: 7 d prior	
American Society of Regional Anesthesia and Pain Medicine, European Society of Regional Anaesthesia and Pain Medicine, American Academy of Pain Medicine, International Neuromodulation Society, North American Neuromodulation Society, and World Institute of Pain 2018	Aspirin: discontinue 6 d prior to high bleeding risk procedures
Clopidogrel: discontinue 7 d prior to moderate-high bleeding risk procedures
(5 d in high thrombotic risk cases)
Ticagrelor: 5 d prior to moderate-high bleeding risk procedures
Prasugrel: 7-10 d prior to moderate-high bleeding risk procedures	
American Society of Regional Anesthesia and Pain Medicine 2018	Continue aspirin
Clopidogrel: discontinue 7 d prior
Ticagrelor: 5 d prior
Prasugrel: 7-10 d prior
Ticlopidine: 10 d prior	
European Society of Anaesthesiology 2010	Continue aspirin
Clopidogrel: discontinue 7 d prior
Ticagrelor: 5 d prior
Prasugrel: 7-10 d prior
Ticlopidine: 10 d prior	
ESAIC, European Society of Anaesthesiology and Intensive Care; ESRA, European Society of Regional Anaesthesia & Pain Therapy; IR, interventional radiology.

5 Bridging

Bridging in the context of perioperative DAPT management refers to interrupting the P2Y12 inhibitor ± ASA and starting an intravenous short-acting antiplatelet agent, which is stopped shortly before surgery. Bridging agents include the GPIIb/IIIa receptor antagonists eptifibatide and tirofiban and the intravenous P2Y12 inhibitor cangrelor. The evidence in support of this strategy was recently reviewed extensively [59], with most data derived from uncontrolled observational studies.

5.1 Eptifibatide

In a propensity-matched analysis of 68 patients who had CABG surgery after PCI and were bridged with eptifibatide, there was no difference reported in rates of red cell or platelet transfusion requirements, but tamponade requiring reoperation was significantly more frequent in the bridged than in the nonbridged group (10% vs 3%). MACE was reported at 7% in the bridged patients and was not published for the control group [60]. Another small study compared 30 patients considered high-risk for cardiovascular events who were bridged with eptifibatide before thoracic surgery with 69 matched controls who did not receive bridging. There was no difference observed in rates of blood product requirements, bleeding, MI, or cardiovascular death. However, the bridged cohort was significantly enriched for the presence of stents, stents placed within the previous year, and clopidogrel administration, suggesting a higher thrombotic risk group [61].

5.2 Tirofiban

Only 1 study using tirofiban for bridging was a retrospective cohort study of 87 patients with prior PCI and stenting within the previous 12 months who were bridged with tirofiban and who were compared with 227 control patients. There was no significant difference in death, MI, or transfusion requirements between the 2 groups. There was a nonsignificant reduction in MACEs between the bridged and nonbridged groups (2.3% vs 7.5%; P = .08) and a significant reduction of net adverse clinical events comprising a composite of MACEs and bleeding with bridging (8.0% vs 22.5%; P < .01), but this later benefit was limited to patients who had stenting within 60 days of surgery [62].

5.3 Cangrelor

Cangrelor, the only available intravenous P2Y12 inhibitor, has advantages over the GPIIb/IIIa inhibitors, including no dose adjustment required in renal impairment [63] and availability of a specific bridging dose and protocol, whereas eptifibatide and tirofiban rely on dosing used in patients with an ACS. The BRIDGE trial randomized 210 patients with ACS or a coronary stent, who required elective CABG, to cangrelor bridging or placebo with a primary safety endpoint of bleeding. There was no significant difference in CABG-related bleeding identified, and rates of thrombotic complications were low, occurring in 2.8% and 4% of the cangrelor and placebo arms respectively, although the study was not powered to assess thrombotic outcomes. Additionally, only half the patients had been stented previously, and the timeframe between PCI and surgery was not reported [64].

In highly selected patients with a high thrombotic risk and a low bleeding risk, bridging with a short-acting antiplatelet agent may be considered. Recommendations from practice guidelines vary widely. The ESC/European Association for Cardio-Thoracic Surgery and ESC/European Society of Anaesthesiology guidelines from 2017 and 2014 [43,65], respectively, suggest consideration of bridging with an intravenous antiplatelet agent if DAPT is discontinued in high-risk individuals, whereas the CHEST suggests against bridging unless in highly selected patients [30]. The 2022 ESC guidelines suggest bridging with eptifibatide or tirofiban may be applicable in rare cases when DAPT cannot be stopped, such as those with a very high risk of stent thrombosis, recurrent MI, or recent PCI; they also consider using a reversible P2Y12 inhibitor, ticagrelor, in which platelet function recovers faster after interruption than with other P2Y12 inhibitors and ASA [29]. In comparison, the Japanese and Australasian guidelines do not recommend bridging at all [66,67]. In the absence of consensus guidelines or a robust body of evidence, we suggest bridging may be considered in those at especially high thrombotic risk, with cangrelor as the preferred agent, if available.

An approach to bridging is shown in Figure 2.Figure 2 Bridging therapy for patients on antiplatelet agents at high risk of thrombosis. GP, glycoprotein; IV, intravenous.

6 Emergency Surgery

Unlike warfarin or direct oral anticoagulants, there are no reversal agents specific to antiplatelet drugs. When patients taking DAPT require emergency surgery after immediate cessation of the P2Y12 inhibitor, nonspecific prohemostatic management options include platelet transfusion or administering tranexamic acid and/or desmopressin (DDAVP). Whether this strategy is likely to improve or potentially restore hemostasis is dependent upon the P2Y12 inhibitor, timing of last antiplatelet dose, and comorbidities.

The evidence in support of platelet transfusion in patients taking P2Y12 inhibitors is sparse but suggests that platelet transfusion may be more beneficial in those taking clopidogrel than the other agents [68,69]. Most available data are from in vitro or ex vivo studies in which uninhibited platelet-rich plasma from healthy subjects was added to samples containing antiplatelet agents. For example, clopidogrel-induced platelet inhibition can be decreased with the addition of 40% noninhibited platelets from platelet-rich plasma [68]. In contrast, prasugrel-induced platelet dysfunction is only partially corrected by 60% noninhibited platelets, and ticagrelor-treated samples did not improve at all. These data, while useful, give no guidance regarding the optimum platelet dose for clinical use [69].

A study of patients receiving antiplatelet agents who presented with intracranial hemorrhage or the need for emergency neurosurgery reported that an average dose of 0.12 IU/kg of platelets effectively restored platelet function using the VerifyNow (Werfen USA LLC) P2Y12 test in patients receiving aspirin monotherapy but did not improve clopidogrel-induced dysfunction sufficiently to restore hemostasis [70]. Similarly, the APTITUDE-CABG study reviewed the impact of platelet transfusion on platelet reactivity in patients taking DAPT experiencing excessive surgical bleeding. An average of 5.5 ± 2.5 platelet concentrates (at 0.7 × 1011 platelets per concentrate) were transfused. Platelet reactivity index improved significantly following transfusion in those receiving clopidogrel but not for prasugrel- and ticagrelor-treated patients [71]. It seems likely that larger doses may be required for those treated with prasugrel than clopidogrel, but formal guidelines are lacking in this area. The issue is further compounded by the fact that the size of platelet concentrates varies from country to country. In the United Kingdom, for example, the minimum requirement for apheresis platelets is 2.4 × 1011, with an average of 3 × 1011 per unit [72]. The 5.5 units administered in the APTITUDE-CABG study thereby equate to 1 to 1.5 units.

In order for platelet transfusions to neutralize the effects of the P2Y12 inhibitors, the active metabolites of these drugs must be at sufficiently low levels in circulating plasma at the time of transfusion. Clopidogrel and prasugrel are irreversible P2Y12 inhibitors; however, their active compounds are only detectable for around 30 minutes and 4 hours after ingestion, respectively [39]. In vitro studies have reported minimal functional platelet recovery if donor platelets are added to blood samples obtained 2 hours after prasugrel administration. The authors, therefore, suggested that 6 hours should have elapsed prior to transfusion in these patients [73]. The same approach has been adopted by the French Working Group on Perioperative Haemostasis guidelines, which also suggest waiting 6 hours in clopidogrel-treated patients where possible [39].

However, while ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel and prasugrel, it is directly active without the need for metabolic activation. Moreover, both ticagrelor and its first active metabolite remain in the circulation for up to 24 hours [[73], [74], [75]]. In the preclinical setting, studies have shown promise only if platelets are administered 24 hours or more after ticagrelor cessation [74,76]. A case report of a patient requiring emergency reversal of DAPT following intracranial hemorrhage demonstrated effective reversal of aspirin effect but failure to improve the platelet reactivity index (vasodilator stimulated phosphoprotein) 28 hours after ticagrelor ingestion, despite transfusion of 8.5 × 1011 platelets (approximately 3 units) [77].

In the event of life- or limb-threatening bleeding in those taking DAPT or the need for emergency surgery, aspirin can be effectively reversed by platelet transfusion. Doing so for the P2Y12 inhibitors requires a higher dose of platelets, more so for prasugrel than clopidogrel, and to ideally wait for 6 hours following the last dose. The optimal dose is not known; however, 2 to 4 units would seem reasonable based upon the available published evidence. Ticagrelor cannot be effectively reversed by platelet transfusion while active metabolite remains in the circulation (see Figure 3).Figure 3 Algorithm for managing urgent surgery while receiving antiplatelet agents.

6.1 Other approaches for ticagrelor reversal

Given the inability of platelet transfusion to neutralize the effect of ticagrelor, alternative approaches are clearly required. DDAVP has not been shown to be effective in this setting, although its use remains in guidelines for intracranial hemorrhage, and the recent phase 2 feasibility study, DASH, demonstrates the ongoing interest in use of DDAVP in this area [[78], [79], [80]]. Equally, recombinant-activated factor VII reduced bleeding in a murine model [81]; however, its use is associated with an increase in arterial thromboembolic events and should generally only be considered as a final resort [82]. Tranexamic acid has been shown to ameliorate inhibition of ADP-induced platelet aggregation using the Multiplate device in patients receiving clopidogrel [83]; however, it had no impact on corresponding thromboelastography-based parameters in ticagrelor-treated samples [84].

Other potential strategies include platelet-mimicking nanosponges, which competitively bind to antiplatelet agents. These nanosponges have a platelet membrane shell and inert perfluorocarbon inner core. They can therefore bind to antiplatelet drugs without the corresponding antiplatelet effect. They have shown promising results in murine models at reversing both ticagrelor and tirofiban-induced antiplatelet effect [85]. Use of external devices to remove antiplatelets from circulation has also been postulated. The CytoSorb (Cytosorbents Corporation) system contains absorbent polymer beads that can remove hydrophobic substances, such as ticagrelor, during cardiopulmonary bypass surgery [86]. Two studies of CytoSorb in ticagrelor-treated patients requiring emergency cardiac surgery, namely ticagrelor CytoSorb haemoadsorption (NCT04131959) and CyTation (NCT04625764), were terminated due to patient recruitment challenges, in part resulting from the SARS-CoV-2 pandemic.

7 Role of Point-of-Care Tests

Point-of-care (POC) testing to guide transfusion during cardiac surgery is now recommended in some consensus guidelines [87], with studies such as the Transfusion Avoidance in Cardiac Surgery trial in over 7000 patients demonstrating the potential value of viscoelastic testing to reduce transfusion burden and major hemorrhage [88]. This may be especially relevant for patients taking clopidogrel and prasugrel, which are prodrugs that are converted into their active metabolites by the cytochrome P450 CYP2C19 enzyme and because single nucleotide polymorphisms within the CYP2C19 gene can significantly affect drug metabolism, leading to variable levels of observed platelet inhibition [89]. Platelet function testing can identify patients with high levels of ADP reactivity despite DAPT who are at increased risk of thrombotic events [90,91]. They may also be of use in patients requiring surgery by predicting bleeding risk and identifying patients who can safely proceed to surgery earlier after drug cessation. There are a number of potential tests described elsewhere [9,92], which are user-dependent and not directly comparable.

The randomized prospective TARGET-CABG study used thromboelastography-platelet mapping to determine level of ADP inhibition in 180 patients who required CABG and were either taking DAPT with clopidogrel or ASA monotherapy. Surgery was scheduled according to the maximum amplitude, with a delay of 24 hours, 3 to 5 days, and >5 days for maximum amplitude results of >50 mm, 35 to 50 mm, and <35 mm, respectively. The average time to surgery in the DAPT cohort was 2.3 days compared with the recommended 5, with no difference in bleeding or transfusion requirements between clopidogrel-treated and clopidogrel-naive cohorts [93]. Another study used platelet function testing (PFA-100, Siemens Healthineers) in 100 clopidogrel-treated patients prior to CABG and compared their outcomes with 100 patients undergoing CABG 5 days after clopidogrel cessation (standard of care) and 100 patients who had not received clopidogrel. The choice of POC was the PFA-100 system using a P2Y cartridge. Assessment of platelet function was associated with a significant reduction in postoperative bleeding and lower packed red cell requirements compared with the standard of care arm and no significant difference compared with the clopidogrel-naive group. Patients waited on average 3.6 days for surgery [94]. Case reports suggest this approach may also be useful for prasugrel-based DAPT [95].

One group assessed preoperative POC (Multiplate) in 226 patients undergoing CABG, of whom 140 were receiving clopidogrel-based DAPT and 86 ticagrelor-based therapy. Bleeding (defined as chest tube loss of more than 450 mL at 6 hours after surgery) was significantly less common among patients with recovered platelet function before surgery irrespective of antiplatelet regimen, with bleeding predicted by ADP test results of <46 U (P = .001) [96]. Reduced ADP- and thrombin receptor activating peptide-induced platelet aggregation preoperatively also predicted severe bleeding in 74 ticagrelor-treated surgical patients with a suggested cutoff level of 25 U and 100 U for ADP and thrombin receptor activating peptide, respectively. This group also reported that postoperative POC testing could similarly identify patients at increased risk of hemorrhage [97]. Although these and other similar studies have identified potential thresholds for bleeding risk, differences in choice of POC modality as well as antiplatelet regimen limit generalization of results. However, if available, these tests may be of use. This may be particularly applicable to patients who require emergency surgery, in whom being able to safely proceed to theater before the routinely suggested drug-free window period has elapsed holds clear advantages.

An approach to emergency surgery is shown in Figure 3.

8 Conclusion

Despite the recent reduction in use of ASA as monotherapy for the management of patients with CVD [98], DAPT use continues to rise [7]. This added complexity in antiplatelet therapy has implications on perioperative management, warranting consideration of temporary interruption of 1 or both antiplatelet drugs. Practice guidelines, in general, provide weak and, sometimes, inconsistent recommendations regarding elective procedures in stable patients, reflecting the limited evidence base. The uncertainty in best practices is greater among those requiring emergency surgery. Unresolved questions include the need for and quantity of platelet transfusion and how to restore platelet function in a timely manner, depending on whether patients are receiving a partially reversible (ticagrelor) or irreversible (clopidogrel, prasugrel) antiplatelet agent. The role of bridging in selected high-risk patients is yet to be defined by designed clinical trials, and uncertainty remains as to which patients, if any, benefit from antiplatelet bridging and which agent and dosing to use. POC testing to assess platelet function, though promising, needs further study, especially outside of a CABG setting. While updated results from the REVERSE-IT study are highly anticipated, there are otherwise very few ongoing clinical trials specifically aimed at addressing these questions, which may continue to plague clinicians for years to come.

Funding

No funding was received.

Author contributions

D.S. and R.T. wrote the manuscript; J.D. provided expert appraisal; J.T. conceived the article and provided expert review.

Relationship Disclosure

D.S.: none. R.T.: none. J.D.: consultancy: Servier Canada, CytoSorb, and Fresenius Kabi; honoraria: Pfizer and LEO Pharma; royalties or licenses: Merck-Manual and Up-to-Date. J.T.: honoraria: LEO Pharma, Bayer, BMS-Pfizer, Boehringer, and Daiichi.

Handling Editor: Dr Michael Makris
==== Refs
References

1 Vaduganathan M. Mensah G.A. Turco J.V. Fuster V. Roth G.A. The global burden of cardiovascular diseases and risk: a compass for future health J Am Coll Cardiol 80 2022 2361 2371 36368511
2 Roth G.A. Mensah G.A. Johnson C.O. Addolorato G. Ammirati E. Baddour L.M. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study J Am Coll Cardiol 76 2020 2982 3021 33309175
3 Ng M. Freeman M.K. Fleming T.D. Robinson M. Dwyer-Lindgren L. Thomson B. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012 JAMA 311 2014 183 192 24399557
4 Giskes K. Kunst A.E. Benach J. Borrell C. Costa G. Dahl E. Trends in smoking behaviour between 1985 and 2000 in nine European countries by education J Epidemiol Community Health 59 2005 395 401 15831689
5 Gu Q. Burt V.L. Dillon C.F. Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010 Circulation 126 2012 2105 2114 23091084
6 Bhatnagar P. Wickramasinghe K. Wilkins E. Townsend N. Trends in the epidemiology of cardiovascular disease in the UK Heart 102 2016 1945 1952 27550425
7 Abrahams T. Brown A. Pol D. Prescribing trends and health care expenditure of P2Y12 prescriptions in Australia over the last decade. Heart Lung Circ 31 2022 1369 1375
8 Savonitto S. Caracciolo M. Cattaneo M. De Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery J Thromb Haemost 9 2011 2133 2142 21819537
9 Swan D. Loughran N. Makris M. Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy Blood Rev 39 2020 100619 10.1016/j.blre.2019.100619
10 Tan C. Cieslik L. Steele S. Warner V. Mariani J. Patel H.C. Contemporary trends in antiplatelet prescription in Australia J Pharm Pract Res 50 2020 366 368
11 Makris M. Van Veen J.J. Tait C.R. Mumford A.D. Laffan M. British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents Br J Haematol 160 2013 35 46 23116425
12 Oprea A.D. Popescu W.M. Perioperative management of antiplatelet therapy Br J Anaesth 111 Suppl 1 2013 i3 i17 24335397
13 Gremmel T. Panzer S. Oral antiplatelet therapy: impact for transfusion medicine Vox Sang 112 2017 511 517 28560760
14 Loll P.J. Picot D. Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase Nat Struct Biol 2 1995 637 643 7552725
15 Gremmel T. Frelinger A.L. 3rd Michelson A.D. Platelet physiology Semin Thromb Hemost 42 2016 191 204 26926581
16 Douketis J.D. Spyropoulos A.C. Spencer F.A. Mayr M. Jaffer A.K. Eckman M.H. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl 2012 e326S e350S 22315266
17 Roffi M. Patrono C. Collet J.P. Mueller C. Valgimigli M. Andreotti F. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 37 2016 267 315 26320110
18 Lee T.H. Marcantonio E.R. Mangione C.M. Thomas E.J. Polanczyk C.A. Cook E.F. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery Circulation 100 1999 1043 1049 10477528
19 Duceppe E. Parlow J. MacDonald P. Lyons K. McMullen M. Srinathan S. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery Can J Cardiol 33 2017 17 32 27865641
20 Hawn M.T. Graham L.A. Richman J.S. Itani K.M.F. Henderson W.G. Maddox T.M. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents JAMA 310 2013 1462 1472 24101118
21 Patel I.J. Rahim S. Davidson J.C. Hanks S.E. Tam A.L. Walker T.G. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe J Vasc Interv Radiol 30 2019 1168 11684.e1 31229333
22 Wilcox T. Smilowitz N.R. Xia Y. Berger J.S. Cardiovascular risk scores to predict perioperative stroke in noncardiac surgery Stroke 50 2019 2002 2006 31234757
23 Halvorsen S. Mehilli J. Cassese S. Hall T.S. Abdelhamid M. Barbato E. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery Eur Heart J 43 2022 3826 3924 36017553
24 Eagle K.A. Berger P.B. Calkins H. Chaitman B.R. Ewy G.A. Fleischmann K.E. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Circulation 105 2002 1257 1267 11889023
25 Tafur A.J. Clark N.P. Spyropoulos A.C. Li N. Kaplovitch E. MacDougall K. Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study J Am Heart Assoc 9 2020 e017316 10.1161/JAHA.120.017316
26 Kaatz S. Douketis J.D. Zhou H. Gage B.F. White R.H. Risk of stroke after surgery in patients with and without chronic atrial fibrillation J Thromb Haemost 8 2010 884 890 20096001
27 Douketis J.D. Spyropoulos A.C. Perioperative management of anticoagulant and antiplatelet therapy NEJM Evid 2 2023 EVIDra2200322 10.1056/EVIDra2200322
28 Keeling D. Tait R.C. Watson H. British Committee of Standards for Haematology. Peri-operative management of anticoagulation and antiplatelet therapy Br J Haematol 175 2016 602 613 27714755
29 Halvorsen S. Mehilli J. Cassese S. Hall T.S. Abdelhamid M. Barbato E. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) Eur Heart J 43 2022 3826 3924 36017553
30 Douketis J.D. Spyropoulos A.C. Murad M.H. Arcelus J.I. Dager W.E. Dunn A.S. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline Chest 162 2022 e207 e243 35964704
31 Kietaibl S. Ferrandis R. Godier A. Llau J. Lobo C. Macfarlane A.J. Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC/ESRA guidelines Eur J Anaesthesiol 39 2022 100 132 34980845
32 Narouze S. Benzon H.T. Provenzano D. Buvanendran A. De Andres J. Deer T. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain Reg Anesth Pain Med 43 2018 225 262 29278603
33 Horlocker T.T. Vandermeuelen E. Kopp S.L. Gogarten W. Leffert L.R. Benzon H.T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition) Reg Anesth Pain Med 43 2018 263 309 29561531
34 Devereaux P.J. Mrkobrada M. Sessler D.I. Leslie K. Alonso-Coello P. Kurz A. Aspirin in patients undergoing noncardiac surgery N Engl J Med 370 2014 1494 1503 24679062
35 Graham M.M. Sessler D.I. Parlow J.L. Biccard B.M. Guyatt G. Leslie K. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery Ann Intern Med 168 2018 237 244 29132159
36 Li C. Hirsh J. Xie C. Johnston M.A. Eikelboom J.W. Reversal of the anti-platelet effects of aspirin and clopidogrel J Thromb Haemost 10 2012 521 528 22268852
37 Le Manach Y. Kahn D. Bachelot-Loza C. Le Sache F. Smadja D.M. Remones V. Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery PloS One 9 2014 e104491 10.1371/journal.pone.0104491
38 Lee J. Kim J.K. Kim J.H. Dunuu T. Park S.H. Park S.J. Recovery time of platelet function after aspirin withdrawal Curr Ther Res Clin Exp 76 2014 26 31 25031665
39 Godier A. Garrigue D. Lasne D. Fontana P. Bonhomme F. Collet J.P. Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR) Arch Cardiovasc Dis 112 2019 199 216 30621917
40 Rossini R. Tarantini G. Musumeci G. Masiero G. Barbato E. Calabrò P. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2 JACC Cardiovasc Interv 11 2018 417 434 29519377
41 Anwaruddin S. Askari A.T. Saudye H. Batizy L. Houghtaling P.L. Alamoudi M. Characterization of post-operative risk associated with prior drug-eluting stent use JACC Cardiovasc Interv 2 2009 542 549 19539259
42 Cassese S. Byrne R.A. Ndrepepa G. Kufner S. Wiebe J. Repp J. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials Lancet 387 2016 537 544 26597771
43 Valgimigli M. Bueno H. Byrne R.A. Collet J.P. Costa F. Jeppsson A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 39 2018 213 260 28886622
44 Fox K.A.A. Mehta S.R. Peters R. Zhao F. Lakkis N. Gersh B.J. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 2004 1202 1208 15313956
45 Held C. Asenblad N. Bassand J.P. Becker R.C. Cannon C.P. Claeys M.J. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial J Am Coll Cardiol 57 2011 672 684 21194870
46 Wiviott S.D. Braunwald E. McCabe C.H. Montalescot G. Ruzyllo W. Gottlieb S. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 17982182
47 Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur Heart J 30 2009 1964 1977 19633016
48 Levine G.N. Bates E.R. Bittl J.A. Brindis R.G. Fihn S.D. Fleisher L.A. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery Circulation 134 2016 e123 e155 27026020
49 Natsuaki M. Watanabe H. Morimoto T. Yamamoto K. Obayashi Y. Nishikawa R. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial Circulation 149 2024 585 600 37994553
50 Watanabe H. Domei T. Morimoto T. Natsuaki M. Shiomi H. Toyota T. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial JAMA 321 2019 2414 2427 31237644
51 Kim B.K. Hong S.J. Cho Y.H. Yun K.H. Kim Y.H. Suh Y. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial JAMA 323 2020 2407 2416 32543684
52 Mehran R. Baber U. Sharma S.K. Cohen D.J. Angiolillo D.J. Briguori C. Ticagrelor with or without aspirin in high-risk patients after PCI N Engl J Med 381 2019 2032 2042 31556978
53 Valgimigli M. Frigoli E. Heg D. Tijssen J. Jüni P. Vranckx P. Dual antiplatelet therapy after PCI in patients at high bleeding risk N Engl J Med 385 2021 1643 1655 34449185
54 Bainey K.R. Marquis-Gravel G. MacDonald B.J. Bewick D. Yan A. Turgeon R.D. Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: systematic review and meta-analysis PloS One 18 2023 e0291061 10.1371/journal.pone.0291061
55 Dodd K.C. Emsley H.C.A. Desborough M.J.R. Chhetri S.K. Periprocedural antithrombotic management for lumbar puncture: Association of British Neurologists clinical guideline Pract Neurol 18 2018 436 446 30154234
56 Horlocker T.T. Wedel D.J. Schroeder D.R. Rose S.H. Elliott B.A. McGregor D.G. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia Anesth Analg 80 1995 303 309 7818117
57 CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (collaborative low-dose aspirin study in pregnancy) collaborative group Lancet 343 1994 619 629 7906809
58 Gogarten W. Vandermeulen E. Van Aken H. Kozek S. Llau J.V. Samama C.M. European Scoeity of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology Eur J Anaesthesiol 27 2010 999 1015 20890208
59 Sullivan A.E. Nanna M.G. Wang T.Y. Bhatt D.L. Angiolillo D.J. Mehran R. Bridging antiplatelet therapy after percutaneous coronary intervention: JACC review topic of the week J Am Coll Cardiol 78 2021 1550 1563 34620413
60 Rassi A.N. Blackstone E. Militello M.A. Theodos G. Cavender M.A. Sun Z. Safety of “bridging” with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery Am J Cardiol 110 2012 485 490 22591672
61 Waldron N.H. Dallas T. Erhunmwunsee L. Wang T.Y. Berry M.F. Welsby I.J. Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients J Thromb Thrombolysis 43 2017 194 202 27798792
62 De Servi S. Morici N. Boschetti E. Rossini R. Martina P. Musumeci G. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: analysis of 314 patients Vascul Pharmacol 80 2016 85 90 26657879
63 Akers W.S. Oh J.J. Oestreich J.H. Ferraris S. Wethington M. Steinhubl S.R. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist J Clin Pharmacol 50 2010 27 35 19779037
64 Angiolillo D.J. Firstenberg M.S. Price M.J. Tummala P.E. Hutyra M. Welsby I.J. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 2012 265 274 22253393
65 Kristensen S.D. Knuuti J. Saraste A. Anker S. Bøtker H.E. Hert S.D. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) Eur Heart J 35 2014 2383 2431 25086026
66 Nakamura M. Kimura K. Kimura T. Ishihara M. Otsuka F. Kozuma K. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease Circ J 84 2020 831 865 32173684
67 Clinical Excellence Commission Guidelines on perioperative management of anticoagulant and antiplatelet agents https://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0006/458988/Guidelines-on-perioperative-management-of-anticoagulant-and-antiplatelet-agents.pdf 2018
68 Vilahur G. Choi B.G. Zafar M.U. Viles-Gonzalez J.F. Vorchheimer D.A. Fuster V. Normalization of platelet reactivity in clopidogrel-treated subjects J Thromb Haemost 5 2007 82 90 17239165
69 Bonhomme F. Bonvini R. Reny J.L. Poncet A. Fontana P. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study Platelets 26 2015 324 330 25905916
70 Taylor G. Osinski D. Thevenin A. Devys J.M. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg 74 2013 1367 1369 23609292
71 O’Connor S.A. Amour J. Mercadier A. Martin R. Kerneis M. Abtan J. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study Circ Cardiovasc Interv 8 2015 e002786 10.1161/CIRCINTERVENTIONS.115.002786
72 Pietersz R.N. Reesink H.W. Panzer S. Gilbertson M.P. Borosak M.E. Wood E.M. Prophylactic platelet transfusions Vox Sang 103 2012 159 176 22519879
73 Zafar M.U. Santos-Gallego C. Vorchheimer D.A. Viles-Gonzalez J.F. Elmariah S. Giannarelli C. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation J Thromb Haemost 11 2013 100 106 23137352
74 Zafar M.U. Smith D.A. Baber U. Sartori S. Chen K. Lam D.W. Impact of timing on the functional recovery achieved with platelet supplementation after treatment with ticagrelor Circ Cardiovasc Interv 10 2017 e005120 10.1161/CIRCINTERVENTIONS.117.005120
75 Dobesh P.P. Oestreich J.H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety Pharmacotherapy 34 2014 1077 1090 25164528
76 Kruger P.C. Hirsh J. Bhagirath V.C. Xu K. Dale B. de Vries T.A.C. In vitro reversal of the anti-aggregant effect of ticagrelor using untreated platelets Thromb Haemost 118 2018 1895 1901 30332695
77 Godier A. Taylor G. Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor N Engl J Med 372 2015 196 197 25564918
78 Teng R. Mitchell P.D. Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor J Clin Pharm Ther 39 2014 186 191 24444280
79 Desborough M.J.R. Al-Shahi Salman R. Stanworth S.J. Havard D. Woodhouse L.J. Craig J. Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial Lancet Neurol 22 2023 557 567 37353276
80 Greenberg S.M. Ziai W.C. Cordonnier C. Dowlatshahi D. Francis B. Goldstein J.N. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association Stroke 53 2022 e282 e361 35579034
81 Pehrsson S. Hansson K. Nelander K. Nylander S. Boosting the coagulation restores haemostasis in ticagrelor-treated mice Blood Coagul Fibrinolysis 27 2016 913 919 26757017
82 Levi M. Levy J.H. Andersen H.F. Truloff D. Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800 21047223
83 Weber C.F. Görlinger K. Byhahn C. Moritz A. Hanke A.A. Zacharowski K. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy Eur J Anaesthesiol 28 2011 57 62 20962655
84 Calmette L. Martin A.C. Le Bonniec B. Zlotnik D. Gouin-Thibault I. Bachelot-Loza C. Ticagrelor reversal: in vitro assessment of four haemostatic agents J Clin Pathol 70 2017 733 739 28159767
85 Xu J. Yan N. Wang C. Gao C. Han X. Yang C. Platelet-mimicking nanosponges for functional reversal of antiplatelet agents Circ Res 132 2023 339 354 36625267
86 Harky A. Badran A. Reducing antithrombotic-related bleeding risk in urgent and emergency cardiac surgery Br J Cardiol 28 2021 26 10.5837/bjc.2021.026 35747456
87 Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA)Boer C. Meesters M.I. Milojevic M. Benedetto U. Bolliger D. von Heymann C. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery J Cardiothorac Vasc Anesth 32 2018 88 120 29029990
88 Karkouti K. Callum J. Wijeysundera D.N. Rao V. Crowther M. Grocott H.P. TACS Investigators Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial Circulation 134 2016 1152 1162 27654344
89 Gurbel P.A. Tantry U.S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287 discussion 87 22412089
90 Tantry U.S. Bonello L. Aradi D. Price M.J. Jeong Y.H. Angiolillo D.J. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273 24076493
91 Stone G.W. Witzenbichler B. Weisz G. Rinaldi M.J. Neumann F.J. Metzger D.C. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623 23890998
92 Mahla E. Tantry U.S. Prüller F. Gurbel P.A. Is there a role for preoperative platelet function testing in patients undergoing cardiac surgery during antiplatelet therapy? Circulation 138 2018 2145 2159 30474416
93 Mahla E. Suarez T.A. Bliden K.P. Rehak P. Metzler H. Sequeira A.J. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study Circ Cardiovasc Interv 5 2012 261 269 22396581
94 Mannacio V. Meier P. Antignano A. Di Tommaso L. De Amicis V. Vosa C. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study J Thorac Cardiovasc Surg 148 2014 1299 1306 24503325
95 Verzelloni Sef A. Caliandro F. Sef D. Raja S.G. The use of point-of-care testing in detecting platelet function recovery in a patient treated with prasugrel undergoing urgent surgical revascularization J Card Surg 36 2021 4801 4804 34580922
96 Della Corte A. Bancone C. Spadafora A. Borrelli M. Galdieri N. Quintiliano S.N. Postoperative bleeding in coronary artery bypass patients on double antiplatelet therapy: predictive value of preoperative aggregometry Eur J Cardiothorac Surg 52 2017 901 908 28977378
97 Björklund E. Hansson E.C. Romlin B.S. Jeppsson A. Malm C.J. Postoperative platelet function is associated with severe bleeding in ticagrelor-treated patients Interact Cardiovasc Thorac Surg 28 2019 709 715 30590527
98 García Rodríguez L.A. Cea Soriano L. de Abajo F.J. Valent F. Hallas J. Gil M. Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study Eur J Clin Pharmacol 78 2022 497 504 34791521
